• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc (NQ: LTRN )

    4.760 +0.140 (+3.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 29,557
    Open 4.590
    Bid (Size) 4.750 (19)
    Ask (Size) 4.860 (3)
    Prev. Close 4.620
    Today's Range 4.340 - 4.850
    52wk Range 2.380 - 11.99
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
    From Lantern Pharma
    Via Business Wire
    Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
    From Lantern Pharma Inc.
    Via Business Wire

    Performance

    YTD
    +14.15%
    +14.15%
    1 Month
    +21.74%
    +21.74%
    3 Month
    -16.78%
    -16.78%
    6 Month
    +14.98%
    +14.98%
    1 Year
    +7.69%
    +7.69%

    More News

    Read More
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Recap: Lantern Pharma Q4 Earnings
    Via Benzinga
    Lantern Pharma Earnings Preview
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024
    Via InvestorPlace
    Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
    From Lantern Pharma Inc.
    Via Business Wire
    Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
    From Lantern Pharma Inc.
    Via Business Wire
    3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
    Via InvestorPlace
    Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
    From Lantern Pharma Inc.
    Via Business Wire
    Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Six Of Seven AI Stock Categories Increased This Week
    Via Talk Markets
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
    Via InvestorPlace
    Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
    From FN Media Group LLC
    Via GlobeNewswire
    Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
    From Lantern Pharma Inc.
    Via Business Wire
    Earnings Scheduled For March 18, 2024
    Via Benzinga
    Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
    From Lantern Pharma Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.